bluebird bio, Inc. (NASDAQ:BLUE) insider Nick Leschly sold 117,500 shares of bluebird bio stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total value of $21,629,400.00. Following the transaction, the insider now owns 293,232 shares of the company’s stock, valued at approximately $53,978,146.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Nick Leschly also recently made the following trade(s):

  • On Wednesday, November 1st, Nick Leschly sold 2,127 shares of bluebird bio stock. The stock was sold at an average price of $145.17, for a total value of $308,776.59.
  • On Friday, October 20th, Nick Leschly sold 3,350 shares of bluebird bio stock. The stock was sold at an average price of $145.02, for a total transaction of $485,817.00.
  • On Monday, October 23rd, Nick Leschly sold 7,050 shares of bluebird bio stock. The shares were sold at an average price of $145.14, for a total transaction of $1,023,237.00.
  • On Tuesday, October 17th, Nick Leschly sold 10,823 shares of bluebird bio stock. The shares were sold at an average price of $145.05, for a total transaction of $1,569,876.15.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded down $0.55 on Friday, reaching $184.35. 1,719,500 shares of the company’s stock traded hands, compared to its average volume of 866,462. bluebird bio, Inc. has a one year low of $60.95 and a one year high of $222.03.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.07) earnings per share. equities analysts anticipate that bluebird bio, Inc. will post -6.72 EPS for the current fiscal year.

A number of analysts have issued reports on BLUE shares. Cowen reissued an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Wedbush reissued an “outperform” rating and issued a $135.00 target price (up previously from $121.00) on shares of bluebird bio in a research report on Friday, September 1st. Wells Fargo & Company reissued an “outperform” rating and issued a $158.00 target price (up previously from $134.00) on shares of bluebird bio in a research report on Tuesday, September 5th. Barclays started coverage on bluebird bio in a research report on Wednesday, September 6th. They issued an “overweight” rating and a $151.00 target price on the stock. Finally, Cantor Fitzgerald reissued a “sell” rating and issued a $39.00 target price on shares of bluebird bio in a research report on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $157.45.

Hedge funds have recently added to or reduced their stakes in the company. QS Investors LLC raised its stake in bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 813 shares during the period. Bank of Montreal Can raised its stake in bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the period. Turner Investments LLC purchased a new position in bluebird bio during the second quarter worth approximately $184,000. Finally, Biondo Investment Advisors LLC purchased a new position in bluebird bio during the third quarter worth approximately $203,000.

COPYRIGHT VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Insider Sells $21,629,400.00 in Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/15/bluebird-bio-inc-blue-insider-sells-21629400-00-in-stock.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.